Could Guardant Health Be a Millionaire-Maker Stock?
It has been less than two years since Guardant Health's (NASDAQ: GH) IPO in October 2018. Since that time, shares of the cancer diagnostic company have returned 298%, compared to the S&P 500's 2.47% return during the same period. A modest investment of $10,000 in Guardant Health's IPO would have grown to $39,863 today.
While the stock has enriched shareholders in the past, I think its winning streak is far from over. Let's take a look at why Guardant is a spectacular buy for investors with a long-term outlook.
Image source: Getty Images.
Source Fool.com
